Suppr超能文献

将降压药物重新用于预防阿尔茨海默病:一项孟德尔随机化研究。

Repurposing antihypertensive drugs for the prevention of Alzheimer's disease: a Mendelian randomization study.

机构信息

Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, UK.

Bristol Medical School: Population Health Sciences, University of Bristol, Bristol, UK.

出版信息

Int J Epidemiol. 2020 Aug 1;49(4):1132-1140. doi: 10.1093/ije/dyz155.

Abstract

BACKGROUND

Evidence concerning the potential repurposing of antihypertensives for Alzheimer's disease prevention is inconclusive. We used Mendelian randomization, which can be more robust to confounding by indication and patient characteristics, to investigate the effects of lowering systolic blood pressure, via the protein targets of different antihypertensive drug classes, on Alzheimer's disease.

METHODS

We used summary statistics from genome-wide association studies of systolic blood pressure and Alzheimer's disease in a two-sample Mendelian randomization analysis. We identified single-nucleotide polymorphisms (SNPs) that mimic the action of antihypertensive protein targets and estimated the effect of lowering systolic blood pressure on Alzheimer's disease in three ways: (i) combining the protein targets of antihypertensive drug classes, (ii) combining all protein targets and (iii) without consideration of the protein targets.

RESULTS

There was limited evidence that lowering systolic blood pressure, via the protein targets of antihypertensive drug classes, affected Alzheimer's disease risk. For example, the protein targets of calcium channel blockers had an odds ratio (OR) per 10 mmHg lower systolic blood pressure of 1.53 [95% confidence interval (CI): 0.94 to 2.49; p = 0.09; SNPs = 17]. We also found limited evidence for an effect when combining all protein targets (OR per 10 mmHg lower systolic blood pressure: 1.14; 95% CI: 0.83 to 1.56; p = 0.41; SNPs = 59) and without consideration of the protein targets (OR per 10 mmHg lower systolic blood pressure: 1.04; 95% CI: 0.95 to 1.13; p = 0.45; SNPs = 153).

CONCLUSIONS

Mendelian randomization suggests that lowering systolic blood pressure via the protein targets of antihypertensive drugs is unlikely to affect the risk of developing Alzheimer's disease. Consequently, if specific antihypertensive drug classes do affect the risk of Alzheimer's disease, they may not do so via systolic blood pressure.

摘要

背景

关于将抗高血压药物重新用于预防阿尔茨海默病的证据尚无定论。我们使用孟德尔随机化(一种可以更有效地控制混杂因素和患者特征的方法)来研究通过降低不同降压药物类别的蛋白靶点的收缩压对阿尔茨海默病的影响。

方法

我们使用了收缩压和阿尔茨海默病的全基因组关联研究的汇总统计数据,进行了两样本孟德尔随机化分析。我们确定了模拟降压蛋白靶点作用的单核苷酸多态性(SNP),并通过三种方式估计降低收缩压对阿尔茨海默病的影响:(i)合并降压药物类别的蛋白靶点,(ii)合并所有蛋白靶点,(iii)不考虑蛋白靶点。

结果

有有限的证据表明,通过降压药物的蛋白靶点降低收缩压会影响阿尔茨海默病的风险。例如,钙通道阻滞剂的蛋白靶点每降低 10mmHg 收缩压的比值比(OR)为 1.53(95%置信区间(CI):0.94 至 2.49;p=0.09;SNP 数量为 17)。当我们合并所有蛋白靶点时,我们也发现了有限的证据表明存在这种影响(每降低 10mmHg 收缩压的 OR:1.14;95% CI:0.83 至 1.56;p=0.41;SNP 数量为 59),而不考虑蛋白靶点时(每降低 10mmHg 收缩压的 OR:1.04;95% CI:0.95 至 1.13;p=0.45;SNP 数量为 153)。

结论

孟德尔随机化表明,通过降压药物的蛋白靶点降低收缩压不太可能影响阿尔茨海默病的发病风险。因此,如果特定的降压药物类别确实会影响阿尔茨海默病的风险,那么它们可能不是通过收缩压起作用的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fd3/7751008/bf3da23fffd8/dyz155f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验